1. Home
  2. WGS vs NNNN Comparison

WGS vs NNNN Comparison

Compare WGS & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$65.62

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$11.49

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WGS
NNNN
Founded
2017
2021
Country
United States
Germany
Employees
1300
27
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WGS
NNNN
Price
$65.62
$11.49
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$120.71
N/A
AVG Volume (30 Days)
1.0M
43.0K
Earning Date
05-04-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.98
N/A
Revenue Next Year
$25.92
N/A
P/E Ratio
$1,251.58
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$32.21
$10.50
52 Week High
$170.87
$55.65

Technical Indicators

Market Signals
Indicator
WGS
NNNN
Relative Strength Index (RSI) 55.31 26.28
Support Level $55.76 $10.50
Resistance Level $73.46 $30.21
Average True Range (ATR) 4.39 1.95
MACD 0.02 -0.03
Stochastic Oscillator 56.54 4.22

Price Performance

Historical Comparison
WGS
NNNN

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: